Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody

Background. Infections are the main cause of death for patients with autoimmune rheumatic diseases. In adult patients with rheumatoid arthritis (RA), mortality caused by respiratory infections is 2–5 times higher than in the population. One of the frequent infectious complications in the course of t...

Full description

Bibliographic Details
Main Authors: Daria D. Vankova, Ekaterina I. Alekseeva, Margarita А. Soloshenko, Tatiana М. Dvoriakovskaia, Ksenia B. Isaeva, Rina V. Denisova, Anna V. Mamutova, Mariya G. Rudnitskaya, Nikolay A. Mayansky, Natal’ya Е. Tkachenko
Format: Article
Language:English
Published: "Paediatrician" Publishers LLC 2018-10-01
Series:Вопросы современной педиатрии
Subjects:
children
pneumococcal infection
vaccination
13-valent pneumococcal conjugate vaccine
tocilizumab
systemic juvenile idiopathic arthritis
clinical case
Online Access:https://vsp.spr-journal.ru/jour/article/view/1930

Internet

https://vsp.spr-journal.ru/jour/article/view/1930

Similar Items